Skip to main content
Bascom Palmer
  • Calendar
  • SPECIALTIES
    Cataracts and Intraocular Lenses Comprehensive Ophthalmology Corneal and External Diseases Glaucoma Neuro-Ophthalmology Ocular Oncology Ophthalmic Pathology Ophthalmic Plastic and Reconstructive Surgery Pediatric Ophthalmology and Strabismus Retina and Vitreous Diseases Uveitis
  • FILTER BY
    Online Grand Rounds Medical Student Education Ophthalmic Images Other Lectures Surgical Videos
  • SEARCH
  • More
Site-wide search Close
Toggle search input
guest access
Log in
Bascom Palmer
Calendar SPECIALTIES Collapse Expand
Cataracts and Intraocular Lenses Comprehensive Ophthalmology Corneal and External Diseases Glaucoma Neuro-Ophthalmology Ocular Oncology Ophthalmic Pathology Ophthalmic Plastic and Reconstructive Surgery Pediatric Ophthalmology and Strabismus Retina and Vitreous Diseases Uveitis
FILTER BY Collapse Expand
Online Grand Rounds Medical Student Education Ophthalmic Images Other Lectures Surgical Videos
SEARCH
Expand all Collapse all
  1. Dashboard
  2. Angio020324
  3. Description
  4. Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies by Ramin Tadayoni, MD, PhD

Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies by Ramin Tadayoni, MD, PhD

Completion requirements
Click on Faricimab in RVO: 72-Week Results From the BALATON and COMINO Phase 3 Studies by Ramin Tadayoni, MD, PhD to open the resource.
◄ 96-week Efficacy and Safety of Aflibercept 8 mg in nAMD: An Update from the PULSAR Study by W. Lloyd Clark, MD
guest access (Log in)
Data retention summary
Powered by Moodle
 
  • Medical Disclaimer
  • |
  • Terms of Use
  • |
  • Privacy Statement
  • |
  • HIPAA Notice of Privacy Practices
  • |
  • About Us
  • |
  • FAQs

© 2026 University of Miami Health Systems. All Rights Reserved.